Drug shows potential as safe, effective for most prevalent form of adult leukemia
Tuesday, December 8, 2015 - 06:20
in Health & Medicine
The new drug acalabrutinib (ACP-196) promotes high response rates that are durable in patients with chronic lymphocytic leukemia (CLL) while producing minimal side effects, new clinical results reveal.